{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:54:09Z","timestamp":1783392849236,"version":"3.54.6"},"reference-count":46,"publisher":"Informa UK Limited","issue":"5","funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.2217\/nmt-2021-0017","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:22:22Z","timestamp":1630927342000},"page":"341-352","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1080","volume":"11","author":[{"given":"Mark","family":"J Tullman","sequence":"first","affiliation":[{"name":"The MS Center for Innovations in Care\rSt. Louis\rMO\r63131\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Zabeti","sequence":"additional","affiliation":[{"name":"University of Cincinnati Gardner Neuroscience Institute\rCincinnati\rOH\r45219\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Vuocolo","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics plc Deerfield\rIL\r60015\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Dinh","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics plc Deerfield\rIL\r60015\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0214-9"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515572406"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.314"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314839"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006574"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2012-048"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000104"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030273"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5120107"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122050"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21802"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21837"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.21307\/ane-2020-023"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145021"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000580"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.141"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001367"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.03.038"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506071174"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00888"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30066-1"},{"key":"e_1_3_3_25_1","unstructured":"ENSPRYNG [package insert]. Genentech Inc CA USA (2020)."},{"key":"e_1_3_3_26_1","unstructured":"SOLIRIS [package insert]. Alexion Pharmaceuticals MA USA (2019)."},{"key":"e_1_3_3_27_1","unstructured":"UPLIZNA [package insert]. Viela Bio Inc. MD USA (2020)."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000918"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.168062"},{"key":"e_1_3_3_35_1","unstructured":"RITUXAN [package insert]. Genentech Inc CA USA (2019)."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/1735-1995.200275"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.5"},{"key":"e_1_3_3_39_1","unstructured":"Yan L WangB SheDet al. Presented at the 8th joint ACTRIMS-ECTRIMS Meeting. Virtual (2020)."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515620934"},{"key":"e_1_3_3_41_1","first-page":"135245852198892","article-title":"Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD","volume":"4","author":"Cree BA","year":"2021","unstructured":"Cree BA , BennettJL, KimHJet al. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult. Scler., 4, 1352458521988926 (2021).","journal-title":"Mult. Scler."},{"key":"e_1_3_3_42_1","unstructured":"Weinshenker B WingerchuckB GreenAet al. Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Stockholm Sweden (2019)."},{"key":"e_1_3_3_43_1","unstructured":"Pittock S PaulF MarignierRet al. Presented at the 8th joint ACTRIMS-ECTRIMS Meeting. Virtual (2020)."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000978"},{"key":"e_1_3_3_45_1","unstructured":"Cree BAC BennettJ WeinshenkerBet al. Poster presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021. FL USA (2021)."},{"key":"e_1_3_3_46_1","unstructured":"Bennett J AktasO ReesWet al. Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Stockholm Sweden (2019)."},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26067"},{"key":"e_1_3_3_48_1","unstructured":"US FDA . FDA approves new therapy for rare disease affecting optic nerve spinal cord (2020). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2021-0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:46:47Z","timestamp":1716493607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2021-0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.2217\/nmt-2021-0017"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2021-0017","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}